AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00713726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
Study NCT00753051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine+haloperidol
Description: clozapine 300-900 mg/d haloperidol 4-60 mg/d
Study NCT00753051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine,electroconvulsive therapy
Description: clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
Study NCT03474471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Following a PR program
Study NCT03474471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBV treatment
Description: Bronchoscopic lung volume reduction using endobronchial valves (EBV)
Study NCT03474471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBV treatment
Description: Bronchoscopic lung volume reduction using endobronchial valves (EBV)
Study NCT00771563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin + docetaxel
Description: docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
Study NCT00771563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + docetaxel + enoxaparin
Description: cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
Study NCT00081874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I.
Study NCT04484831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABT Weight Loss Intervention
Description: This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
Study NCT04484831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Care
Description: This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
Study NCT03040622 — intervention group
Intervention type: DEVICE
Intervention: WATCHMAN Left Atrial Appendage Closure
Description: WATCHMAN Left Atrial Appendage Closure
Study NCT03861819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity interval training (VIIT)
Description: Subjects will be fitted with a heart rate monitor around the chest and a baseline 4ml blood sample will be drawn. Vigorous intensity interval training will correspond to heart rate (HR) range of 80-90% of heart rate at age-predicted heart rate maximum (220-age). After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total. A 4ml blood sample will be drawn immediately following the exercise session and 2-hours after exercise cessation.
Study NCT02750150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freezed-dried plasma
Description: early transfusion of 4 units of freezed dried plasma
Study NCT02750150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fresh-frozen plasma
Study NCT03565731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-PA
Description: The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
Study NCT01972711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-36385625 as a single oral dose of 50 mg
Study NCT01972711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Amisulpride as a single oral dose of 400 mg
Study NCT01972711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose placebo
Study NCT02110147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uridine triacetate
Study NCT01793220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
Study NCT03279133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90mg/Sofosubvir 400mg
Description: Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
Study NCT04555538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
Study NCT01833715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine group,receive morphine 0.08 mg / kg at the start of surgery
Study NCT01833715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone group,receive methadone 0.08 mg / kg at the start of surgery
Study NCT01833715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA
Description: TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
Study NCT01833715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
Study NCT02594163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Study NCT02594163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02594163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT02594163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study NCT02594163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Study NCT03566810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GXR
Description: Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study NCT03566810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GXR
Description: Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study NCT00171704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablets and supplied in bottles with 6-monthly supplies.
Study NCT00171704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
Study NCT01652950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: \<150 fitness points per month - equivalent to \< 1 gym visit per month - no reward, up to Level 5, which was >3000 fitness points/month - equivalent to >20 gym visits/month.
Study NCT01652950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentives
Description: The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: \<150 fitness points per month - equivalent to \< 1 gym visit per month - no reward, up to Level 5, which was >3000 fitness points/month - equivalent to >20 gym visits/month.
Study NCT01652950 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial incentives
Description: The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: \<150 fitness points per month - equivalent to \< 1 gym visit per month - no reward, up to Level 5, which was >3000 fitness points/month - equivalent to >20 gym visits/month.
Study NCT03763838 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure
Description: Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
Study NCT03763838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Fatigue management provided by participants' health care providers.
Study NCT03763838 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care
Description: Fatigue management provided by participants' health care providers.
Study NCT03763838 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Fatigue management provided by participants' health care providers.
Study NCT03006003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene tratment more than 4 weeks
Study NCT03006003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronic acid 70mg with Colecalciferol 70mcg
Study NCT02586298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous mitochondria with ICSI
Description: Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
Study NCT02586298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD ICSI PROCEDURE
Description: STANDARD ICSI PROCEDURE
Study NCT01658033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin + mFOLFOX6
Description: mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w
Study NCT03367663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 20 Mg
Description: Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
Study NCT03367663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 40 Mg
Description: Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
Study NCT02686749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF.
Study NCT02686749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved anti arrhythmic drug
Description: Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
Study NCT04074889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: (Microbial cell preparation) Probiotics
Description: Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
Study NCT04074889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet with no microbial cell preparation
Study NCT03142763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Consumption of 3 eggs per day for breakfast, 4 weeks
Study NCT03142763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline Supplement
Description: Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
Study NCT00895674 — intervention group
Intervention type: DRUG
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Patients with a diagnosis of advanced RCC
Study NCT04112329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
Study NCT02591199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URG101
Study NCT02591199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02591199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT02591199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT00265447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: 3 months of strength training
Study NCT00265447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic conditioning
Description: 3 months of aerobic conditioning
Study NCT00265447 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed exercise
Description: delayed exercise control group
Study NCT02749630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to UTTR1147A administered intravenously
Study NCT02749630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: Escalating doses of intravenously administered UTTR1147A
Study NCT03296891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PoCUS Guided Resuscitation of Shock
Description: Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
Study NCT00215878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D-serine (~2g /day)
Description: Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
Study NCT00215878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine (~2g /day)
Description: Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
Study NCT02315027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: single dose of 1 × 10(7) cells intrathecally
Study NCT02315027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: 2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart
Study NCT02315027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: 2 doses of 1 × 10(8) cells intrathecally each 1 month apart
Study NCT02315027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
Study NCT02315027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
Study NCT04768387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Personalized microbiome diet
Description: The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
Study NCT04768387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Personalized microbiome diet
Description: The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
Study NCT00893282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BackStop
Description: BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
Study NCT00893282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intracorporeal lithotripsy without the use of an anti-retropulsion device
Study NCT04124393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon Polypectomy
Description: Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.